These data show that synthetic lethality can be achieved in BRCA2-deficient prostate tumor cells by reactivation of the SAC with PP2Ai, suggesting that PP2A is an attractive synthetic lethal therapeutic target for prostate cancer patients with BRCA2 mutations. Here, PTPA is linked to prostate carcinoma.